Nothing Special   »   [go: up one dir, main page]

Previous Issue
Volume 2, September
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 

Gout Urate Cryst. Depos. Dis., Volume 2, Issue 4 (December 2024) – 4 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
16 pages, 899 KiB  
Review
Year in Review 2023: Gout Clinical Research
by Greg Challener and Chio Yokose
Gout Urate Cryst. Depos. Dis. 2024, 2(4), 354-369; https://doi.org/10.3390/gucdd2040025 - 8 Nov 2024
Viewed by 723
Abstract
Gout is the most common inflammatory arthritis, with a growing global disease burden. This conference report summarizes nine impactful publications dating from 11/2022 to 10/2023 to inform and improve clinical care in gout. The articles we present here collectively address diverse facets of [...] Read more.
Gout is the most common inflammatory arthritis, with a growing global disease burden. This conference report summarizes nine impactful publications dating from 11/2022 to 10/2023 to inform and improve clinical care in gout. The articles we present here collectively address diverse facets of gout research, including gout epidemiology, predictive biomarkers, the occurrence of complications relating to gout flares, and gout management strategies. Full article
Show Figures

Figure 1

Figure 1
<p>Trends in gout prevalence by race and ethnicity (Reprinted from [<a href="#B3-gucdd-02-00025" class="html-bibr">3</a>]).</p>
Full article ">Figure 2
<p>Results of the main analysis of the self-controlled case series data. a: Events of venous thromboembolism. b: Analyses of adjusted incidence rate ratios, adjusted for age and calendar season. c: The induction period was defined as 15 days preceding the gout flare date. d: The baseline period included a pre-exposure period of up to 715 days preceding the induction period, as well as a post-exposure period of up to 730 days (Reprinted from [<a href="#B26-gucdd-02-00025" class="html-bibr">26</a>]).</p>
Full article ">
15 pages, 2173 KiB  
Article
Assessing Changes in Vascular Inflammation and Urate Deposition in the Vasculature of Gout Patients After Administration of Pegloticase Using Positron Emission Tomography and Dual-Energy Computed Tomography—A Pilot Study
by Ira Khanna, Venkatesh Mani, Renata Pyzik, Audrey Kaufman, Weiwei Chi, Emilia Bagiella, Philip Robson and Yousaf Ali
Gout Urate Cryst. Depos. Dis. 2024, 2(4), 339-353; https://doi.org/10.3390/gucdd2040024 - 6 Nov 2024
Viewed by 785
Abstract
We assessed changes in vascular inflammation and monosodium urate (MSU)-coded deposits after administration of Pegloticase in the vasculature of tophaceous gout patients using 18F-fluorodeoxyglucose (18F-FDG) Positron emission tomography/computed tomography (PET/CT) and dual-energy CT (DECT). Ten patients with tophaceous gout, intolerant [...] Read more.
We assessed changes in vascular inflammation and monosodium urate (MSU)-coded deposits after administration of Pegloticase in the vasculature of tophaceous gout patients using 18F-fluorodeoxyglucose (18F-FDG) Positron emission tomography/computed tomography (PET/CT) and dual-energy CT (DECT). Ten patients with tophaceous gout, intolerant or refractory to urate-lowering therapy (ULT), were treated with Pegloticase every two weeks for six months. 18F-FDG PET/CT and DECT were performed at baseline and after Pegloticase therapy to detect vessel wall inflammation (Standard uptake value, SUVmean, and SUVmax) and vascular MSU-coded deposition (MSU volume). Data were summarized using means and standard deviations. Baseline and follow-up values were compared for each variable using mixed-effect models. Significant decreases in SUVmean (p = 0.0003) and SUVmax (p = 0.009) were found with a trend towards a decrease in vessel wall MSU volume after treatment. There was a significant decrease in serum urate, correlating with reduction in SUVmean (R2 = 0.65), with a trend towards a decrease in CRP and blood pressure in all patients. Despite the small sample size, we were able to demonstrate a decrease in vessel wall inflammation and a trend towards a decrease in MSU volume by intensively lowering serum urate. These findings suggest that MSU-coded deposits and hyperuricemia may play a role in vascular wall inflammation. It remains to be seen whether this correlates with a decrease in adverse cardiovascular outcomes. Full article
Show Figures

Figure 1

Figure 1
<p>(<b>A</b>) <sup>18</sup>F-FDG uptake and (<b>B</b>) MSU volume on a patient level before and after treatment with Pegloticase. Reductions in SUVmean (averaged over all vessels) and MSU volume (total volume for each patient) after treatment with Pegloticase were not statistically significant, <span class="html-italic">p</span> = 0.14 and <span class="html-italic">p</span> = 0.68, respectively. (<b>C</b>) <sup>18</sup>F-FDG uptake in vessel segments with MSU deposits before and after treatment were not statistically significant, <span class="html-italic">p</span> = 0.86. Plots show median and inter-quartile range.</p>
Full article ">Figure 2
<p>(<b>A</b>) Analysis of blood biomarkers for all patients before (baseline) and after Pegloticase infusions (follow-up). By paired <span class="html-italic">t</span>-tests, uric acid is the only marker that drops significantly after treatment (<span class="html-italic">p</span> = 0.006). (<b>B</b>) In a sub-analysis of patients who completed at least 10 infusions, uric acid remains the only statistically significant change (<span class="html-italic">p</span> = 0.027). Biomarkers [units]: Sys BP = systolic blood pressure [mmHg]. Dias BP = diastolic blood pressure [mmHg], LDL = low density lipoprotein [mg/dL], TG = triglycerides [mg/dL], HbA1c = hemoglobin A1c [%], hs-CRP = high-sensitivity C-reactive protein [mg/L], uric acid [mg/dL].</p>
Full article ">Figure 3
<p>Correlation between changes from baseline to after treatment in <sup>18</sup>F-FDG uptake (SUVmean) in vessel segments showing MSU-coded deposits and in uric acid. Moderate correlations were found for all patients with vessel segments showing MSU deposits (R<sup>2</sup> = 0.51) and for patients completing at least 10 visits (R<sup>2</sup> = 0.65).</p>
Full article ">Figure 4
<p>Representative PET/CT (left) and DECT images (right) from axial locations in five vessel levels in four patients. (<b>A</b>) <sup>18</sup>F-FDG uptake (orange overlay) shows inflammation in the right iliac artery (green arrow). On DECT, MSU-coded deposits (green) are shown in the corresponding vessel walls (green arrow), with bone (calcium) shown in purple. In this location, imaging shows a decrease in <sup>18</sup>F-FDG uptake and MSU volume from baseline to follow-up following treatment with Pegloticase. (<b>B</b>) <sup>18</sup>F-FDG uptake showing inflammation and DECT showing an MSU-coded deposit in the abdominal aorta (green arrows). In this patient, the deposit which was identified as MSU-coded at baseline, which likely had mixed calcium and MSU characteristics, appeared to resolve after treatment. <sup>18</sup>F-FDG uptake in a small segment (~2 cm) of vessel centered on the location of the MSU-coded deposit showed a reduction in SUVmean from 1.81 to 1.68 and in SUVmax from 2.60 to 2.55. (<b>C</b>) <sup>18</sup>F-FDG uptake in the abdominal aorta (green arrow) is reduced at follow-up (SUVmean/SUVmax pre: 1.65/2.17, post: 1.57/2.00) while MSU-coded deposit resolves. (<b>D</b>) In the descending thoracic aorta, little change is seen in <sup>18</sup>F-FDG signal (SUVmean/SUVmax pre: 1.69/2.24, post: 1.64/2.26) while MSU-coded deposit volume increases from 1.3 mm<sup>3</sup> to 3.4 mm<sup>3</sup>. (<b>E</b>) In the left femoral artery another MSU deposit resolves after treatment while <sup>18</sup>F-FDG signal reduces slightly (SUVmean/SUVmax pre: 1.64/2.30, post: 1.64/2.25).</p>
Full article ">Figure 4 Cont.
<p>Representative PET/CT (left) and DECT images (right) from axial locations in five vessel levels in four patients. (<b>A</b>) <sup>18</sup>F-FDG uptake (orange overlay) shows inflammation in the right iliac artery (green arrow). On DECT, MSU-coded deposits (green) are shown in the corresponding vessel walls (green arrow), with bone (calcium) shown in purple. In this location, imaging shows a decrease in <sup>18</sup>F-FDG uptake and MSU volume from baseline to follow-up following treatment with Pegloticase. (<b>B</b>) <sup>18</sup>F-FDG uptake showing inflammation and DECT showing an MSU-coded deposit in the abdominal aorta (green arrows). In this patient, the deposit which was identified as MSU-coded at baseline, which likely had mixed calcium and MSU characteristics, appeared to resolve after treatment. <sup>18</sup>F-FDG uptake in a small segment (~2 cm) of vessel centered on the location of the MSU-coded deposit showed a reduction in SUVmean from 1.81 to 1.68 and in SUVmax from 2.60 to 2.55. (<b>C</b>) <sup>18</sup>F-FDG uptake in the abdominal aorta (green arrow) is reduced at follow-up (SUVmean/SUVmax pre: 1.65/2.17, post: 1.57/2.00) while MSU-coded deposit resolves. (<b>D</b>) In the descending thoracic aorta, little change is seen in <sup>18</sup>F-FDG signal (SUVmean/SUVmax pre: 1.69/2.24, post: 1.64/2.26) while MSU-coded deposit volume increases from 1.3 mm<sup>3</sup> to 3.4 mm<sup>3</sup>. (<b>E</b>) In the left femoral artery another MSU deposit resolves after treatment while <sup>18</sup>F-FDG signal reduces slightly (SUVmean/SUVmax pre: 1.64/2.30, post: 1.64/2.25).</p>
Full article ">
14 pages, 1712 KiB  
Review
Epigenomic Reprogramming in Gout
by Ancuta R. Straton, Brenda Kischkel, Tania O. Crișan and Leo A. B. Joosten
Gout Urate Cryst. Depos. Dis. 2024, 2(4), 325-338; https://doi.org/10.3390/gucdd2040023 - 1 Nov 2024
Viewed by 442
Abstract
Gout is a crystal-induced arthropathy in which monosodium urate (MSU) crystals precipitate within joints as a result of persistent hyperuricemia and elicit an inflammatory response. An intriguing aspect is the occurrence of gout in only 10–15% of hyperuricemic individuals, suggesting the presence of [...] Read more.
Gout is a crystal-induced arthropathy in which monosodium urate (MSU) crystals precipitate within joints as a result of persistent hyperuricemia and elicit an inflammatory response. An intriguing aspect is the occurrence of gout in only 10–15% of hyperuricemic individuals, suggesting the presence of additional risk factors. Although MSU crystal deposition is widely recognized as the cause of gout flares, the variability in initiating the inflammatory response to hyperuricemia and MSU deposition is not well understood. Several studies bring up-to-date information about the environmental and genetic influences on the progression towards clinical gout. Elevated urate concentrations and exposure to different external factors precipitate gout flares, highlighting the potential involvement of epigenetic mechanisms in gouty inflammation. A better understanding of the alteration of the epigenetic landscape in gout may provide new perspectives on the dysregulated inflammatory response. In this review, we focus on understanding the current view of the role of epigenomic reprogramming in gout and the mechanistic pathways of action. Full article
Show Figures

Figure 1

Figure 1
<p>Systemic and local inflammation model in gout. Serum urate and MSU crystals can activate NF-kB in immune cells in a single step, thereby inducing transcription of pro-IL-1beta cleaved by caspase 1 and enhancing cytokine production. Additionally, in urate-primed monocytes, transcriptional regulation of the Akt-PRAS40 pathway is associated with upregulation of IL-1beta and downregulation of IL-1Ra by phosphorylation of Akt and PRAS 40, consequently activating mTOR and shifting the phenotype to a more pro-inflammatory state. Locally, suprasaturation of urate results in the deposition of MSU crystals, which are then phagocytosed. Macrophage activation requires 2 steps; initially, DAMPs/PAMPs trigger formation of inflammasome elements, and a second stimulus (MSU) activates NLRP3 inflammasome that cleaves caspase 1 and leads to IL-1beta secretion. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB); mammalian target of rapamycin (mTOR); protein kinase B (Akt); proline-rich AKT substrate 40 kDa (PRAS 40). DAMPs: damage-associated molecular patterns; PAMPs, Pathogen Associated Molecular Patterns.</p>
Full article ">Figure 2
<p>Overview of the epigenetic changes described in gout. Studies have shown that differential DNA methylation in gout patients can be associated with increased expression of genes related to the inflammatory response and may explain the persistent inflammation status caused by urate exposure. In this figure, we list the genes described so far and discussed in this review that contribute to the enhancement of the inflammatory response. Histone modifications are another epigenetic process in which only H3K9 trimethylation and H3K27 acetylation have been explored in the context of urate-treated cells. In this figure, we list the genes mentioned in this review that showed differential enrichment of these marks. Non-coding RNAs are an epigenetic modification that has gained more attention in recent decades. Some ncRNAs have been suggested as potential biomarkers for gout modulators of inflammation.</p>
Full article ">
10 pages, 1712 KiB  
Article
A Novel Polarized Light Microscope for the Examination of Birefringent Crystals in Synovial Fluid
by John D. FitzGerald, Chesca Barrios, Tairan Liu, Ann Rosenthal, Geraldine M. McCarthy, Lillian Chen, Bijie Bai, Guangdong Ma and Aydogan Ozcan
Gout Urate Cryst. Depos. Dis. 2024, 2(4), 315-324; https://doi.org/10.3390/gucdd2040022 - 22 Oct 2024
Viewed by 798
Abstract
Background: The gold standard for crystal arthritis diagnosis relies on the identification of either monosodium urate (MSU) or calcium pyrophosphate (CPP) crystals in synovial fluid. With the goal of enhanced crystal detection, we adapted a standard compensated polarized light microscope (CPLM) with a [...] Read more.
Background: The gold standard for crystal arthritis diagnosis relies on the identification of either monosodium urate (MSU) or calcium pyrophosphate (CPP) crystals in synovial fluid. With the goal of enhanced crystal detection, we adapted a standard compensated polarized light microscope (CPLM) with a polarized digital camera and multi-focal depth imaging capabilities to create digital images from synovial fluid mounted on microscope slides. Using this single-shot computational polarized light microscopy (SCPLM) method, we compared rates of crystal detection and raters’ preference for image. Methods: Microscope slides from patients with either CPP, MSU, or no crystals in synovial fluid were acquired using CPLM and SCPLM methodologies. Detection rate, sensitivity, and specificity were evaluated by presenting expert crystal raters with (randomly sorted) CPLM and SCPLM digital images, from FOV above clinical samples. For each FOV and each method, each rater was asked to identify crystal suspects and their level of certainty for each crystal suspect and crystal type (MSU vs. CPP). Results: For the 283 crystal suspects evaluated, SCPLM resulted in higher crystal detection rates than did CPLM, for both CPP (51%. vs. 28%) and MSU (78% vs. 46%) crystals. Similarly, sensitivity was greater for SCPLM for CPP (0.63 vs. 0.35) and MSU (0.88 vs. 0.52) without giving up much specificity resulting in higher AUC. Conclusions: Subjective and objective measures of greater detection and higher certainty were observed for SCPLM over CPLM, particularly for CPP crystals. The digital data associated with these images can ultimately be incorporated into an automated crystal detection system that provides a quantitative report on crystal count, size, and morphology. Full article
Show Figures

Figure 1

Figure 1
<p>Single-shot computational polarized light microscopy (SCPLM) setup and schematic diagram. (<b>A</b>) Single-shot computational polarized light microscopy (SCPLM) setup. (<b>B</b>) Schematic diagram of the SCPLM setup.</p>
Full article ">Figure 2
<p><b>Top</b> row: Side-by-side CPLM (magenta) and SCPLM (grey) comparison images (CPPD patient). <b>Bottom</b> row: Side-by-side CPLM (magenta) and SCPLM (grey) comparison images (MSU patient).</p>
Full article ">Figure 3
<p>Crystal Identification Workflow and Final Crystal Specific Analytic Sample Selection Clinical Source. * 37/196 crystals with low certainty scores (1 or 2). <sup>†</sup> 10/87 crystals with low certainty scores. <sup>‡</sup> 10/10 crystals with low certainty scores and excluded from crystal-specific analyses. Legend: CPPD = calcium pyrophosphate deposition. MSU = monosodium urate. FOV = field of view. C/S = crystal suspect. UNK = unknown. Neg Ctrl = negative control.</p>
Full article ">
Previous Issue
Back to TopTop